S-1联合奥沙利铂方案一线治疗晚期胃癌 有效性及安全性分析

目的探讨S-1联合奥沙利铂方案一线治疗晚期胃癌的有效性及安全性.方法选取60例晚期胃癌患者作为研究对象,随机将其分为研究组和对照组,研究组采用S-1+L-OHP方案进行治疗,对照组采用FOL-FOX方案进行治疗.结果研究组和对照组患者有效率比较差异无统计学意义(P0.05);研究组疾病控制率为80.0%,优于对照组的53.3%,且差异具有统计学意义(P0.05);研究组和对照组中位TTP比较差异具有统计学意义(P0.05);两组中位OS比较差异无统计学意义(P0.05);研究组外周神经毒性发生率明显高于对照组,差异具有统计学意义(P0.05),其余不良反应发生率比较差异均无统计学意义(P0.05).结论 S-1联合奥沙利铂治疗晚期胃癌具有良好的疗效及安全性,与FOL-FOX方案比较,不良反应低,且静脉滴注时间短,患者依从性好.

Efficacy and Safety of S-1 Combined with Oxaliplatin as the First-Line Treatment in Advanced Gastric Cancer

Objective To explore the efficacy and safety of S-1 combined with oxaliplatin as the first-line treatment in advanced gastric cancer. Method 60 cases of advanced gastric cancer patients were selected as the research object,which were randomly divided into study group and control group. The patients in the study group was treated with S-1+L-OHP and those in the control group was treated with FOL-FOX. Results There was no significant difference in the effective rate between the study group and the control group (P>0. 05). The disease control rate (80%) of patients in the study group was better than that (53. 3%)in the control group (P<0. 05). The difference in the median TTP ( time-to-progression) between the study group and control group was statistically significant (P<0. 05). There was no significant difference in the median OS between the two groups (P>0. 05). The incidence of peripheral neurotoxicity in the study group was significantly higher than that in the control group (P<0. 05 ), and the incidences of other adverse reactions were not statistically significant ( P>0. 05 ). Conclusion S-1 combined with oxaliplatin in the treatment shows a good effect and safety in advanced gastric cancer, with some advantages compared with FOL-FOX, such as less adverse reactions, shorter intravenous infusion duration,convenience due to the oral administration and good patients' compliance.